These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 36258702)

  • 21. Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Harr T; French LE
    Chem Immunol Allergy; 2012; 97():149-66. PubMed ID: 22613860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cutaneous Immune-Related Adverse Events (irAEs) to Immune Checkpoint Inhibitors: A Dermatology Perspective on Management [Formula: see text].
    Muntyanu A; Netchiporouk E; Gerstein W; Gniadecki R; Litvinov IV
    J Cutan Med Surg; 2021; 25(1):59-76. PubMed ID: 32746624
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of the acute ocular manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis in Chinese eyes: a 15-year retrospective study.
    Chow LLW; Shih KC; Chan JCY; Lai JSM; Ng ALK
    BMC Ophthalmol; 2017 May; 17(1):65. PubMed ID: 28499410
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recurrent Steven-Johnson/Toxic Epidermal Necrolysis Overlap Syndrome.
    Toledo-Martinez JF; Galdamez-Carcamo EV; Somoza-Cano FJ; Padilla-Mantilla DA; Alvarenga-Alvarado KL
    Cureus; 2022 Jan; 14(1):e21364. PubMed ID: 35198278
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Retrospective Cohort Study of the Management and Outcomes of Children Hospitalized with Stevens-Johnson Syndrome or Toxic Epidermal Necrolysis.
    Antoon JW; Goldman JL; Shah SS; Lee B
    J Allergy Clin Immunol Pract; 2019 Jan; 7(1):244-250.e1. PubMed ID: 29859332
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Steven Johnson Syndrome and Toxic Epidermal Necrolysis in a burn unit: A 15-year experience.
    McCullough M; Burg M; Lin E; Peng D; Garner W
    Burns; 2017 Feb; 43(1):200-205. PubMed ID: 27554629
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Deflazacort-induced Steven-Johnson syndrome: a case report and literature review].
    Li CW; Sun N; Li SN; Zhang YC; Ma JJ
    Zhonghua Er Ke Za Zhi; 2024 Nov; 62(11):1103-1107. PubMed ID: 39429084
    [No Abstract]   [Full Text] [Related]  

  • 28. Improving mortality outcomes of Stevens Johnson syndrome/toxic epidermal necrolysis: A regional burns centre experience.
    Nizamoglu M; Ward JA; Frew Q; Gerrish H; Martin N; Shaw A; Barnes D; Shelly O; Philp B; El-Muttardi N; Dziewulski P
    Burns; 2018 May; 44(3):603-611. PubMed ID: 29029855
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Severe cutaneous adverse drug reactions manifesting as Stevens-Johnson syndrome and toxic epidermal necrolysis reported to the national pharmacovigilance center in Nigeria: a database review from 2004 to 2017.
    Oshikoya KA; Ogunyinka IA; Ogar CK; Abiola A; Ibrahim A; Oreagba IA
    Ther Adv Drug Saf; 2020; 11():2042098620905998. PubMed ID: 32110375
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Drug-induced Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS-TEN overlap: a multicentric retrospective study.
    Barvaliya M; Sanmukhani J; Patel T; Paliwal N; Shah H; Tripathi C
    J Postgrad Med; 2011; 57(2):115-9. PubMed ID: 21654132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Retrospective analysis of Steven Johnson syndrome and toxic epidermal necrolysis over a period of 5 years from northern Karnataka, India.
    Naveen KN; Pai VV; Rai V; Athanikar SB
    Indian J Pharmacol; 2013; 45(1):80-2. PubMed ID: 23543919
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Colistin-associated Stevens-Johnson syndrome and toxic epidermal necrolysis reactions: a retrospective case-non-case pharmacovigilance study.
    Tang R; Lopes VL; Caffrey AR
    Expert Opin Drug Saf; 2022 Aug; 21(8):1121-1126. PubMed ID: 35196183
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nine years of a single referral center management of Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).
    Monteiro D; Egipto P; Barbosa J; Horta R; Amarante J; Silva P; Silva A
    Cutan Ocul Toxicol; 2017 Jun; 36(2):163-168. PubMed ID: 27487073
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with lupus erythematosus: a descriptive study of 17 cases from a national registry and review of the literature.
    Ziemer M; Kardaun SH; Liss Y; Mockenhaupt M
    Br J Dermatol; 2012 Mar; 166(3):575-600. PubMed ID: 22014091
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features of Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Sato S; Kanbe T; Tamaki Z; Furuichi M; Uejima Y; Suganuma E; Takano T; Kawano Y
    Pediatr Int; 2018 Aug; 60(8):697-702. PubMed ID: 29888432
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in the Era of Systems Medicine.
    Chen CB; Wang CW; Chung WH
    Methods Mol Biol; 2022; 2486():37-54. PubMed ID: 35437717
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Steven Johnson Syndrome in a 102-Year-Old Woman in Saudi Arabia: A Case Report.
    Alnofaiey YH; AlTalhi WA; Altalhi WA; Alsulaimani AI; Alkhaldi LM
    Cureus; 2022 Dec; 14(12):e32303. PubMed ID: 36628019
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Making Rash Decisions in Epilepsy: Evaluating Hypersensitivity Reactions to Anti-seizure Medications.
    Bermeo-Ovalle A
    Epilepsy Curr; 2019; 19(2):96-98. PubMed ID: 30955419
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study.
    Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Concise Review with a Comprehensive Summary of Therapeutic Interventions Emphasizing Supportive Measures.
    Schneider JA; Cohen PR
    Adv Ther; 2017 Jun; 34(6):1235-1244. PubMed ID: 28439852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.